Can-Fite BioPharma Ltd.
Health Care · Biotechnology
Structural: nano-cap Israeli biotech with proprietary A3 adenosine receptor platform; dual NASDAQ/TASE listing provides visibility but float is extremely thin.
CF101 NASH readout could be transformative in an underserved indication; A3AR mechanism is differentiated vs. GLP-1 wave; low base market cap means binary upside on a positive trial.
Phase II NASH data historically poor across the industry; cash runway risk for sub-$10M market-cap company; Israeli geopolitical risk premium; dilution via ATM is near-certain.
No key levels recorded for this ticker.